With NJ Court of Appeals Hagen decision potentially changing the trajectory of insurance reimbursement of medical cannabis, two of our portfolio companies partnered on medical data and research.
CB2 Insights, a data-driven portfolio company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, announced on January 14 that it has partnered with Licensed Producer and fellow Merida portfolio company, Vireo Health International Inc., to advance the proof of safety and efficacy for cannabinoid therapy as it relates to metered-dosing for patients with ailments in which cannabis-based medicine is believed to support.
CB2 will oversee the protocol development and Investigational New Drug (IND) Application directly with the US Food & Drug Administration (FDA). The successful completion will position Vireo for industry leadership when it comes to cannabis-based topical medication used to treat pain. Vireo will also license the Company’s Sail technology platform for full data collection and management.